{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=46",
    "query": {
      "intervention": "Placebo- matched",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 7061,
    "total_pages": 707,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T17:20:36.089Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00851890",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "ABT-333",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ABT-333",
          "type": "OTHER"
        },
        {
          "name": "Pegylated interferon",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2009-03",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-11-12T17:20:36.089Z",
      "location_count": 7,
      "location_summary": "Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00851890"
    },
    {
      "nct_id": "NCT05462990",
      "title": "A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "QUC398",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 101,
      "start_date": "2022-11-09",
      "completion_date": "2025-04-08",
      "has_results": true,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-11-12T17:20:36.089Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Boston, Massachusetts • Morehead City, North Carolina",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05462990"
    },
    {
      "nct_id": "NCT04537208",
      "title": "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 (Healthy Volunteers)"
      ],
      "interventions": [
        {
          "name": "CoV2 preS dTM-AF03 (low-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM-AF03 (high-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM-AS03 (low-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM-AS03 (high-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM (high-dose) without adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% normal saline)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 441,
      "start_date": "2020-09-03",
      "completion_date": "2021-11-19",
      "has_results": true,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-11-12T17:20:36.089Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04537208"
    },
    {
      "nct_id": "NCT07222189",
      "title": "A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colitis Ulcerative",
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "balinatunfib",
          "type": "DRUG"
        },
        {
          "name": "balinatunfib-matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "19 Years to 77 Years"
      },
      "enrollment_count": 7,
      "start_date": "2026-05-19",
      "completion_date": "2026-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-11-12T17:20:36.089Z",
      "location_count": 1,
      "location_summary": "Southlake, Texas",
      "locations": [
        {
          "city": "Southlake",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222189"
    },
    {
      "nct_id": "NCT01892189",
      "title": "Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ketamine-Induced Brain Activity Changes",
        "Psychotic-like Symptoms"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "TAK-063",
          "type": "DRUG"
        },
        {
          "name": "TAK-063 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2013-08",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-11-12T17:20:36.089Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892189"
    },
    {
      "nct_id": "NCT03136991",
      "title": "A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "AZD4831",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 38,
      "start_date": "2017-05-15",
      "completion_date": "2017-11-22",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-11-12T17:20:36.089Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03136991"
    },
    {
      "nct_id": "NCT02951182",
      "title": "A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "TEZ",
          "type": "DRUG"
        },
        {
          "name": "IVA",
          "type": "DRUG"
        },
        {
          "name": "VX-440",
          "type": "DRUG"
        },
        {
          "name": "Matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2016-10",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2020-08-28",
      "last_synced_at": "2026-11-12T17:20:36.089Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02951182"
    },
    {
      "nct_id": "NCT07850063",
      "title": "ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Metabolic Dysfunction-associated Steatotic Liver Disease"
      ],
      "interventions": [
        {
          "name": "Survodutide",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo matching survodutide",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2026-11-18",
      "completion_date": "2029-04-29",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-12T17:20:36.089Z",
      "location_count": 23,
      "location_summary": "Flagstaff, Arizona • Peoria, Arizona • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07850063"
    },
    {
      "nct_id": "NCT00276406",
      "title": "Use of Pyridostigmine for Constipation in Diabetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Constipation",
        "Diabetes Mellitus",
        "Colonic Transit",
        "Gastric Emptying"
      ],
      "interventions": [
        {
          "name": "Pyridostigmine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-05",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2012-11-30",
      "last_synced_at": "2026-11-12T17:20:36.089Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00276406"
    },
    {
      "nct_id": "NCT04775706",
      "title": "Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Short Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "HM15912 Active",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2022-03-03",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-11-12T17:20:36.089Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Cleveland, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04775706"
    }
  ]
}